Allogeneic hematopoietic stem cell transplantation provides the best chance of long-term survival for patients with AML, but is associated with an unpredictable risk of treatment-related mortality. From January 2000 to December 2010, we compared the outcomes for patients with AML aged 35 and over using reduced-intensity conditioning (RIC, N = 60) or conventional myeloablative conditioning (MAC) regimen (N = 72) transplantation. The median follow-up was 47 months (10-134). The 4-year cumulative incidence of non-relapse mortality was 21%. After adjusting for cytogenetic risk, gender donor/recipient mismatch and CD34+ cells, non-relapse mortality was significantly lower with the RIC regimen (P = 0.027). The 4-year cumulative incidence of relapse was 38% and no difference was observed in the adjusted relapse rate between the two groups. The 4-year OS rate was 46%. Using both Cox regression and inverse probability-of-treatment weighted (IPTW) method, a similar OS rate was found with both regimens (adjusted hazard ratios for conventional vs reduced of 1.14 (95% CI 0.67-1.93, P = 0.64) with Cox regression, and 1.14 (95% CI 0.55-2.34, P = 0.73) with IPTW). Until prospective trials are completed, this study supports the use of a reduced-intensity regimen prior to transplantation for patients with AML aged 35 and over.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) provides the best chance for long-term survival and offers the lowest risk of relapse for patients with high-risk AML. 1 Advances in genomic technologies have identified AML as a genetically heterogenous disease: many patients can now be classified into prognostic subgroups on the basis of their underlying molecular genetic defects, 2 although the indication for HSCT in all intermediate-risk patients in first remission of AML is still debated. 3 The major limitation of HSCT is the risk of treatment-related mortality (TRM), especially among older candidates with comorbidities. 4 As the incidence of AML is highest in people older than 60, reduced-intensity conditioning (RIC) regimens have been developed for over a decade in order to decrease TRM. 5 These regimens are now increasingly used to facilitate HSCT in patients with advanced age or medical comorbidities, primarily because RIC regimens are well tolerated and are associated with less toxicity. 6, 7 Previously published retrospective analyses suggested similar survival rates, but with a significantly higher risk of relapse after RIC regimen for patients aged 50 and over with AML 8 or for patients with myelodysplastic syndromes. 9 Using unrelated donors (URDs), another retrospective study reported a higher relapse rate in AML patients younger than 50 years after RIC regimen, with a similar leukemia-free survival between the two regimens. 10 However, the use of RIC regimens has not been extensively studied in younger patients with AML. This population is classically treated with conventional high-intensity regimens in the absence of comorbidities or a history of severe fungal infections. Conversely, young patients are also exposed to a risk of TRM: biological markers such as pre-transplant C-reactive protein, 11 ferritin levels 12 and more recently, the pre-transplantation recipient telomere length have been studied in this setting to identify and prevent this risk. 13 In this study, we compared the outcomes for all patients with AML aged 35 and over who received either a RIC or a myeloablative conditioning (MAC) regimen before allogeneic transplantation in our center between 2000 and 2010 in order to analyze the role of the conditioning regimen intensity in this setting.
MATERIALS AND METHODS

Study cohort
Between January 2000 and December 2010, all consecutive patients aged 35 and over with AML who received an allo-HSCT with matched (10/10) donors were included in the study. Biphenotypic AML, cord blood as the source of stem cells, related and unrelated mismatched donors, as well as second allogeneic transplantations were excluded from the study. This study was conducted at Saint-Louis Hospital (Paris, France) in accordance with the Declaration of Helsinki. Patients gave their informed consent in line with approved protocols drawn up by the Saint-Louis Hospital Institutional Review Board. HLA-matching All related donors were HLA-matched siblings based on family studies. Histocompatibility testing and selection of URDs are described in detail elsewhere.
14 Recipients and URDs were defined as matched (10/10) if HLA-A, -B, -C, -DQB1 and -DRB1 were identical at molecular level.
Study end points and definitions
The intensity of the conditioning regimen was defined as previously described, based on consensus criteria. 15 Conditioning regimens are detailed in Table 1 . The different indications to select one of the regimens were related to a different time period of the study. Anti-thymocyte globulin was added when a 'Slavin' type conditioning regimen was used, irrespective of donor type (unrelated or related). 5 Regarding the MAC regimen, anti-thymocyte globulin was used for patients transplanted with an URD since 2008. Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were diagnosed and graded according to published criteria, 16 with histopathologic confirmation where possible. Non-relapse mortality (NRM) was considered as any death occurring before disease relapse. CR and relapse were defined according to criteria published by Cheson et al. 17 Disease risks were defined as favorable, intermediate and poor for AML in first CR. 18 Secondary AML (n = 18) was defined as AML with prior myelodysplastic syndrome, or with prior cytotoxic therapy for a different disorder. Karnofsky performance status was evaluated in the 2 weeks prior to beginning the conditioning regimen. Abbreviations: CS = corticosteroids; EBMT = European Group for Blood and Marrow Transplantation; EDX = Endoxan; FLU = fludarabine; MAC = myeloablative conditioning; MEL = melphalan; MMF = mycophenolate mofetil; RIC = reduced-intensity conditioning.
Months from transplant
Non−relapse mortality 
Statistical analysis
Baseline characteristics of patients receiving RIC or MAC were compared using Wilcoxon rank-sum tests and Fisher's exact tests. Time-to-event outcomes were counted from the date of transplant to the date of event or date of last follow-up, except engrafment and aGVHD, which were arbitrarily censored at 120 days. Other outcomes were censored at 72 months, given the study FU. OS was estimated using the Kaplan-Meier estimator and cumulative incidence functions (CIFs) using usual methodology. 19 Factors associated with outcomes were analyzed using proportional-hazard or cause-specific hazard models. 20 The proportional Abbreviations: aHR = adjusted HR; CI = confidence interval; CIF = cumulative incidence function; CS = corticosteroids; EBMT = European Group for Blood and Marrow Transplantation; HR = hazard ratio; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; RIC = reduced-intensity conditioning. Abbreviations: aHR = adjusted HR; CI = confidence interval; CIF = cumulative incidence function; CS = corticosteroids; EBMT = European Group for Blood and Marrow Transplantation; HR = hazard ratio; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; NE = non-estimable; NPH = non-proportional hazard; RIC = reduced-intensity conditioning.
hazards assumption was tested for each predictor. All factors with P-values ⩽ 0.20 in the univariable analyses were considered in multivariable analyses. Mononuclear cell doses were not included in the multivariate analysis because all but one patient with RIC received PBSC, as did 46% in the MAC group. Conversely, the distribution of CD34+ cell doses largely overlapped (between groups, but also cell source), so models were also adjusted for this variable. To confirm the comparison of RIC vs MAC for OS obtained by adjusted Cox analyses, we also adjusted for baseline confounding by the inverse probability-of-treatment weighted (IPTW) method. 21 This approach involves weighting each patient in the Cox model by the inverse probability of having received the conditioning they actually received, conditional on their baseline factors. Weights were obtained by using logistic regression with conditioning as response variable and all baseline variables associated with either conditioning or survival as explanatory variables. Stem cell source, however, was not used because all but one patient with RIC received PBSC. Weights were then stabilized to avoid bias and to reduce the variability of estimates. Direct adjusted OS curves, as well as adjusted OS curves corresponding to IPTW analyses, were also estimated. P-values were two-sided with a significance level of 0.05. Analyses were performed using the R statistical software version 2.15.0.
RESULTS
Patient characteristics
A total of 132 consecutive patients who received an allogeneic BM (n = 40) or a PBSC (n = 92) transplantation from an HLA-identical sibling (n = 87) or from a 10/10 HLA-matched URD (n = 45) were included in the analysis. The patients received an allo-HSCT after MAC (n = 72) or RIC (n = 60) regimens. In the group of patients who received a RIC regimen, 13 patients were aged o50; 12 of them received a RIC regimen because of at least one comorbid condition (four pulmonary comorbidities, three hepatic comorbidities, two renal abnormalities, two heart disease and two infections), and one of them was unspecified. Median age was 48 (range 35-66). Subjects, diseases and transplantation characteristics are summarized in Table 1 . Concerning the type of conditioning regimen, there was no difference regarding gender, AML subtypes (de novo AML vs secondary AML), disease status at transplantation, Karnofsky performance status at HSCT, donor type, donor/recipient gender match, EBMT risk score, 22 donor/ recipient CMV status and the number of CD34+ cells infused. Cytogenetic risks were comparable between the two groups. Conversely, patients in the MAC group were younger (median age 44 (range 35-56) vs 54 (37-66) for RIC, P o 0.0001), received mainly BM as the source of stem cells (54 vs 2% for RIC, Po 0.0001), had a younger donor (39 vs 49 years, P = 0.002), and GVHD prophylaxis mainly comprised CsA plus MTX (89 vs 5% for RIC, P o 0.0001). Moreover, the dose of anti-thymoglobulin in the conditioning regimen (higher in RIC: 51 vs 14%, P o 0.0001) and the number of infused nucleated cells (higher in RIC: 11 vs 4 × 10 8 / kg, P o 0.0001) also differed between the two groups.
Engraftment and GVHD Median follow-up was 47 months (range 10-134), and 25% of patients had at least 74 months of follow-up. All patients engrafted successfully. The CIF of aGVHD grade II-IV was 49% (95% CI 40-57) with 35% after RIC vs 61% after MAC (P = 0.001; Figure 1 ). Adjusting for cytogenetic risk, gender donor/recipient mismatch and CD34+ cells, we nevertheless observed significantly less aGVHD with RIC than with MAC (hazard ratio (HR) 2.5, P = 0.0006). Of particular note, we found a higher rate of aGVHD in secondary AML compared with de novo AML (HR 2.04, P = 0.033; Table 2 ). The 4-year CIF of cGVHD was 37% (40% after RIC vs 28% after MAC, P = 0.32). No risk factor was associated with cGVHD (Supplementary material).
NRM, relapse and OS During follow-up, 71 patients died, including 28 patients who died without relapse, corresponding to a 4-year CIF of NRM of 21% (13% after RIC vs 28% after MAC, P = 0.009) (Figure 2 ). Adjusting for cytogenetic risk, gender donor/recipient mismatch and CD34+ cells, we found a significant higher rate of NRM in the MAC group (P = 0.027). Gender mismatch (female donor to male recipient, P = 0.038) was the only factor independently associated with a reduced rate of NRM (Table 3) .
The 4-year CIF of relapse was 38% (44% after RIC vs 33% after MAC (P = 0.22); Figure 3 ). Female donor to male recipient was associated with a significantly higher risk of relapse (67% vs 32%, P = 0.006). Negative donor/positive recipient CMV status and CD34+ cell dose 48 × 10 6 /kg were associated with a significantly lower risk of relapse (HR 0.32, P = 0.026 and HR 0.35, P = 0.006, respectively). After adjustment, no difference was observed between RIC and MAC (HR 0.8, 95% CI 0.4-1.5, P = 0.50) ( Table 4 ).
The 4-year OS was 46% (50% after RIC vs 43% after MAC, P = 0.38). Using both Cox regression and IPTW to account for imbalances in patient characteristics, similar OS was found after Abbreviations: aHR = adjusted HR; CI = confidence interval; CIF = cumulative incidence function; CS = corticosteroids; EBMT = European Group for Blood and Marrow Transplantation; HR = hazard ratio; MAC = myeloablative conditioning; MMF = mycophenolate mofetil; RIC = reduced-intensity conditioning.
RIC and MAC (Figure 4) , with adjusted HRs for MAC vs RIC of 1.14 (95% CI 0.67-1.93, P = 0.64) with Cox regression, and an HR of 1.14 (95% CI 0.55-2.34, P = 0.73) with IPTW.
DISCUSSION
Our results show that RIC and MAC conditioning regimens led to similar outcomes for patients with AML aged 35 and over who were transplanted in our center between 2000 and 2010, either from siblings or matched URDs. We observed a significant higher rate of aGVHD and NRM with MAC regimen, but relapse rates did not differ according to the intensity of the conditioning regimen. Overall, both types of regimen resulted in similar 4-year survival rates. TRM is usually advanced as the main reason not to proceed to HSCT in older patients, but also in younger patients with impaired organ function or prior severe infectious complications. 23 Several studies have established both the feasibility and efficacy of RIC regimens from matched sibling donors [5] [6] [7] as well as from URDs 24,25 based on the GVL effect. 26 However, some retrospective studies suggest that despite lower TRM, the risk of relapse may increase due to the reduced dose intensity of the conditioning regimen, especially in patients with uncontrolled disease. [8] [9] [10] More recently, a retrospective study in a heterogeneous population of AML and myelodysplastic syndrome suggested that a RIC regimen may contribute to optimal survival, as no difference in disease-free survival and less toxicity was observed after RIC. 27 In our study, adjusted NRM was significantly higher with MAC than with RIC (P = 0.027). We also observed a significantly higher rate of aGVHD after the MAC regimen, especially in patients with secondary AML, as already reported, 8, 27 but this did not translate into a higher rate of cGVHD. 'Late acute GVHD' described in 2005 may explain part of the difference between RIC and MAC. 28 However, we were unable to reclassify GVHD status according to the NIH classification in this retrospective study.
Moreover, relapse rates were similar in both regimens. We observed a lower rate of relapse with CMV negative donor/ positive recipient status (P = 0.043), with no clear explanation provided by previous reports. A recent study supported the choice of a CMV seropositive donor for a CMV seropositive patient if the patient receives a MAC regimen with no significant differences in terms of relapse. 29 As previously reported, 30 a higher CD34+ cell dose in our study was associated with a lower relapse rate. Surprisingly, female donor to male recipient was associated with a significantly higher risk of relapse. However, in the statistical analysis, relapse was in fact mainly associated with male recipients rather than with gender mismatches. A recent study looking at aGVHD and cGVHD in 45000 patients reported a greater impact on relapse rates and DFS after RIC, 31 suggesting the importance of the GVHD-associated GVL effect with RIC, in comparison with MAC, and its importance in limiting both early and late leukemia recurrence.
There are no published randomized controlled trials comparing true reduced-intensity conditioning, as defined by Bacigalupo et al, 15 with standard conditioning in patients with AML. A recent randomized comparison between a standard conditioning regimen and an 8 Gy TBI with fludarabine-based reducedintensity conditioning suggested equivalent efficacy of the two regimens in terms of overall outcome, early toxic effects and mortality. 32 However, the RIC definition in this latter study is highly debatable regarding the dose of TBI (⩾5 Gy single dose or ⩾ 8 Gy fractionated) and may therefore be defined as myeloablative according to a consensus panel. 15 A prospective study by the Groupe Ouest-Est d'étude des Leucémies Aiguës et autres Maladies du Sang (GOELAMS) compared RIC (oral BU: 8 mg/kg over 2 days, fludarabine: 120 mg/m 2 total dose over 4 days and rabbit anti-thymocyte globulin: 2.5 mg/kg on days 4 and 3) in patients aged 50 and over (N = 47) with MAC in younger patients (N = 117). 33 As in our study, the probability of relapse in older patients was similar to that of the younger group who received a myeloablative regimen, while there was a trend for increased toxicity after a myeloablative regimen. However, this study was randomized according to recipients' ages and therefore did not evaluate the RIC regimen in younger patients. In our study,~20% of the patients were under 50 in the RIC group, while 15% of patients received a MAC regimen after 50 years, with no difference in terms of outcomes.
Our work has strengths and limitations. Our study included a homogeneous cohort, enrolled in our center with specified diagnostic criteria, complete characteristics of the disease, supportive care and prospectively determined and defined clinical outcomes. We monitor our patients indefinitely at specified intervals, while our policy requires periodic assessment for adverse events such as relapse and late toxicity. An important limitation of our study is its non-randomized setting and the relative limited number of patients, which offers the potential for the introduction of bias. We did not observe any difference in OS rates with MAC or RIC, while the major bias of our study is the age of the two populations, directly related to the choice between types of conditioning regimen. Nearly, 20% of patients were under 50 in the RIC group because of comorbid conditions. Until recently, pulmonary function tests were not performed for our patients before allogeneic HSCT per protocol but rather according to the physician's suspicion of altered pulmonary function. This is why the comorbidity score and the Seattle comorbidity score are not available in our study. However, the EBMT score 22 was similar in the two groups, which suggests that the choice of regimen was mainly due to age, rather than due to the risk of HSCT for an individual patient pre-transplant. Two different methods were used to overcome the imbalance between the two groups: regression adjustment and inverse-probability-of-treatment weighted method. Both methods work differently but can reduce confounding bias. Regression adjustment, using Cox modeling in this study, relies on an assumed relationship between confounders and the outcome. As such, it is prone to misspecification, although no violation model assumptions were detected in the study. Conversely, IPTW aims to reconstruct a population with a similar structure in both groups by overweighting patients with a low probability of receiving the conditioning they actually received. In both cases, the results we obtained were very similar, which may indicate a certain degree of robustness.
Overall, these data suggest comparable outcomes when using MAC or RIC regimen in patients aged 35 and over with AML between 2000 and 2010 at our center. Notably, this study did not show any benefit in using a more intensive regimen in terms of relapse rate. Until prospective trials are completed, this study supports the RIC regimen in patients aged 35 and over with AML.
